Cargando…
What can we learn from phase II adjuvant trials in melanoma?
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2000
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374544/ https://www.ncbi.nlm.nih.gov/pubmed/10883660 http://dx.doi.org/10.1054/bjoc.2000.1277 |
| _version_ | 1782154478800076800 |
|---|---|
| author | Keilholz, U Suciu, S Eggermont, A M M |
| author_facet | Keilholz, U Suciu, S Eggermont, A M M |
| author_sort | Keilholz, U |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2374544 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2000 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23745442009-09-10 What can we learn from phase II adjuvant trials in melanoma? Keilholz, U Suciu, S Eggermont, A M M Br J Cancer Editorial Nature Publishing Group 2000-07 2000-06-02 /pmc/articles/PMC2374544/ /pubmed/10883660 http://dx.doi.org/10.1054/bjoc.2000.1277 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Editorial Keilholz, U Suciu, S Eggermont, A M M What can we learn from phase II adjuvant trials in melanoma? |
| title | What can we learn from phase II adjuvant trials in melanoma? |
| title_full | What can we learn from phase II adjuvant trials in melanoma? |
| title_fullStr | What can we learn from phase II adjuvant trials in melanoma? |
| title_full_unstemmed | What can we learn from phase II adjuvant trials in melanoma? |
| title_short | What can we learn from phase II adjuvant trials in melanoma? |
| title_sort | what can we learn from phase ii adjuvant trials in melanoma? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374544/ https://www.ncbi.nlm.nih.gov/pubmed/10883660 http://dx.doi.org/10.1054/bjoc.2000.1277 |
| work_keys_str_mv | AT keilholzu whatcanwelearnfromphaseiiadjuvanttrialsinmelanoma AT sucius whatcanwelearnfromphaseiiadjuvanttrialsinmelanoma AT eggermontamm whatcanwelearnfromphaseiiadjuvanttrialsinmelanoma |